Expression of soluble therapeutic proteins

US8043833B2 · kind B2 · utility

Assignee

• Novo Nordisk A/S · DK

Inventors

• Marc F. Schwartz · Plainsboro, US
• Bingyuan Wu · Spring House, US
• Aliakbar Mobasseri · Voorhees, US
• Shawn DeFrees · North Wales, US
• Tarik Soliman · Chester Springs, US
• Karl F. Johnson · Willoughby Hills, US

Key dates

• Filing date: Sep 6, 2006
• Grant date: Oct 25, 2011
• Expiry date: Aug 30, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K14/755
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The present invention provides enhanced methods of producing soluble, active fibroblast growth factor-20 (FGF-20), FGF-21, neurotrophin-3 (NT-3), growth hormone (GH), granulocyte colony stimulating factor (G-CSF), or glucocerebrosidase proteins in microorganisms that have an oxidizing environment.